Antibody Drug Conjugate Data in Endometrial Cancer: TROPiCS-03
Expert Ritu Salani, MD, MBA, reviews data from TROPiCS-03 and considers the potential role for antibody drug conjugates in patients with advanced endometrial cancer.
EP: 1.Patient Case: A 64-Year-Old Woman With Recurrent Endometrial Cancer
EP: 2.Endometrial Cancer: Factors in Selecting First- and Second-Line Therapy
EP: 3.Immune Checkpoint Inhibitors in Recurrent Endometrial Cancer: Clinical Trial Data
EP: 4.Recurrent Endometrial Cancer: An Evolving Treatment Landscape
EP: 5.Combination IO Strategies in Advanced Endometrial Cancer: RUBY and GY018
EP: 6.Single-Agent IO Therapy in Advanced Endometrial Cancer: PHAEDRA and DOMENICA
EP: 7.Adjuvant IO Strategies in Endometrial Cancer: RAINBO and GY020
EP: 8.Antibody Drug Conjugate Data in Endometrial Cancer: TROPiCS-03
EP: 9.Future Directions in the Management of Endometrial Cancer
Transcript:
Ritu Salani, MD, MBA: I know we've talked a lot about immunotherapy, but the last thing I want to highlight is the use of sacituzumab govitecan in patients with metastatic solid tumors. This is phase 2 basket study, and it's known as TROPiCS-03. It is an early analysis in patients with advanced metastatic endometrial cancer and this study is really exciting. Sacituzumab, which we call Sassy, targets Trop-2 in tumors. This has been highly expressed in endometrial cancer, although there's some data that suggests that Trop-2 expression may not correlate with response rates. This is an antibody-drug conjugate that targets Trop-2. It's nice to have a nonimmunotherapy agent that's on the horizon as well.
What we're seeing with Sassy in this setting is some really impressive clinical response rates. The data is still early, but it may help inform practice and offer another therapy for our patients when they recur, even in the frontline setting if we can find biomarker-specific patients who may benefit the most from this.
Transcript edited for clarity.
FDA Accepts sBLA of Dostarlimab/Chemo to Include All Advanced Endometrial Cancer
April 24th 2024The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a Prescription Drug User Fee Act action date of August 23, 2024.
Read More
Roundtable Roundup: Surveying Oncologists on Endometrial Cancer Treatment
March 27th 2024Bhavana Pothuri, MD, and Krishnansu S. Tewari, MD, discussed the treatment options of a patient with advanced endometrial cancer and participants chose an immune checkpoint inhibitor to use for therapy.
Read More
Ghamande Reviews Latest Chemoimmunotherapy Trials for Endometrial Cancer
March 19th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Sharad A. Ghamande, MD, discussed the significance of the NRG-GY018/KEYNOTE-868 and RUBY trials of immune checkpoint inhibitor plus chemotherapy in patients with advanced endometrial cancer.
Read More
